Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

MLA

Lee, Caroline A., et al. “Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design.” Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 43, no. 4, Apr. 2015, pp. 490–509. EBSCOhost, https://doi.org/10.1124/dmd.114.062174.

APA

Lee, C. A., O’Connor, M. A., Ritchie, T. K., Galetin, A., Cook, J. A., Ragueneau-Majlessi, I., Ellens, H., Feng, B., Taub, M. E., Paine, M. F., Polli, J. W., Ware, J. A., & Zamek-Gliszczynski, M. J. (2015). Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 43(4), 490–509. https://doi.org/10.1124/dmd.114.062174

Chicago

Lee, Caroline A, Meeghan A O’Connor, Tasha K Ritchie, Aleksandra Galetin, Jack A Cook, Isabelle Ragueneau-Majlessi, Harma Ellens, et al. 2015. “Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 43 (4): 490–509. doi:10.1124/dmd.114.062174.